We further assessed the effect of PI3K-activation in non-obese patients with FIGO stage 1, grade 1-2 tumors, and similarly in FIGO stage 1, ERα positive tumors, as almost all cancer-related deaths in these subgroups were observed in patients with BMI 20-30. Here, ESR1 is linked to cancer.